A better understanding of the pathological processes involved in IBD has led to the development of new biological agents in ulcerative colitis and Crohn’s disease. Discover how anti-integrins are changing the way inflammatory bowel disease is treated, and why a gut-selective treatment option may offer a promising choice. You can also explore the other emerging anti-integrin treatments that are currently being investigated in clinical trials.
Natalizumab is an IgG4 recombinant human anti-α4 integrin monoclonal antibody that is not gut-selective.
Vedolizumab is a gut-selective humanised immunoglobulin (Ig) G1 monoclonal antibody that binds to α4β7 integrin expressed on the surface of leukocytes.
Etrolizumab, PF-00547659 (SHP647), Abrilumab (AMG 181/MEDI 7183), PTG-100 and AJM300 are currently in development.